Skin · Melanocortin receptor agonist · Research guide
PT-141
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist, developed by Palatin Technologies. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Watch
Mechanism
- Melanocortin 4 receptor (MC4R) agonism. Central mechanism affecting sexual arousal pathways.
Common research protocols
Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.
- FDA-approved dosing (Vyleesi). 1.75 mg subcutaneous, on-demand, at least 45 minutes before anticipated activity, up to 1 dose per 24 hours and 8 doses per month.
Evidence at a glance
- Regulatory. FDA-approved 2019.
- Known side effects. Nausea (common), flushing, injection-site reactions, transient blood pressure elevation.
Reconstitution & handling
Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How We Work page.
Primary-literature list for this guide available on request via contact.
Further reading — external professional sources
- Bremelanotide (INN name) — Wikipedia
- PubMed — search "bremelanotide OR PT-141"
- ClinicalTrials.gov — trials for "bremelanotide"
- FDA Drugs@FDA — bremelanotide
Links open in a new tab. Private Supply is not affiliated with these sources.